RESUMEN
BACKGROUND: For patients with resected stage III colon cancer, 6 months of adjuvant fluoropyrimidine-based chemotherapy has been the standard of care. The IDEA collaboration aimed to evaluate whether 3 months of adjuvant chemotherapy was noninferior to 6 months. Despite failing to meet its primary endpoint, the subgroup analyses demonstrated noninferiority based on regimen and treatment duration when a risk-stratified approach was used. PATIENTS AND METHODS: To evaluate the impact of the results of the IDEA collaboration, we evaluated adjuvant chemotherapy prescribing practice patterns, including planned adjuvant treatment regimen and duration from January 1, 2016, to January 31, 2021. The time period was selected to evaluate chemotherapy prescribing patterns prior to the abstract presentation of the IDEA collaboration in June 2017 and after full manuscript publication in March 2018. RESULTS: A total of 399 patients with stage III colon cancer who received adjuvant chemotherapy were included in the analysis. A significant increasing trend for use of 3 months of adjuvant chemotherapy was observed after presentation of the IDEA abstract (P<.001). A significant change in CAPOX (capecitabine/oxaliplatin) prescribing was also observed, increasing from 14% of patients prior to presentation of the IDEA abstract to 48% after presentation (P<.001). Comparing 3 months of CAPOX with 6 months of FOLFOX (fluorouracil/leucovorin/oxaliplatin), 3 months of CAPOX use also steadily increased over time (adjusted odds ratio [aOR], 1.28; 95% CI, 1.20-1.37; P<.001). Among subgroups of interest, no differences in adoption of CAPOX were observed. The adoption of 3 months of CAPOX was similar in patients with low-risk cancer (aOR, 1.27; 95% CI, 1.17-1.37) and those with high-risk cancer (aOR, 1.31; 95% CI, 1.16-1.47). CONCLUSIONS: Despite the IDEA collaboration failing to demonstrate noninferiority of 3 months' duration of adjuvant therapy compared with 6 months, the findings have influenced practice prescribing patterns, favoring CAPOX and a shorter duration of planned adjuvant treatment.
Asunto(s)
Neoplasias del Colon , Fluorouracilo , Humanos , Fluorouracilo/uso terapéutico , Oxaliplatino/uso terapéutico , Supervivencia sin Enfermedad , Estadificación de Neoplasias , Neoplasias del Colon/terapia , Capecitabina/uso terapéutico , Quimioterapia Adyuvante/métodos , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Leucovorina/uso terapéuticoRESUMEN
Head and neck cancer (HNC) is the seventh most common malignancy, with oropharyngeal squamous cell carcinoma (OPSCC) accounting for a majority of cases in the western world. While HNC accounts for only 5% of all cancers in the United States, the incidence of a subset of OPSCC caused by human papillomavirus (HPV) is increasing rapidly. The treatment for OPSCC is multifaceted, with a recently emerging focus on immunotherapeutic approaches. With the increased incidence of HPV-related OPSCC and the approval of immunotherapy in the management of recurrent and metastatic HNC, there has been rising interest in exploring the role of immunotherapy in the treatment of HPV-related OPSCC specifically. The immune microenvironment in HPV-related disease is distinct from that in HPV-negative OPSCC, which has prompted further research into various immunotherapeutics. This review focuses on HPV-related OPSCC, its immune characteristics, and current challenges and future opportunities for immunotherapeutic applications in this virus-driven cancer.
RESUMEN
Worldwide accumulation of e-waste poses a major threat to environmental health. However, printed circuit boards contain precious metals, such as gold, and silver, and also contain micronutrient metal elements, such as Fe, Cu, Zn, etc. Therefore, the present study investigated the effects of e-waste-tolerant bacteria (ETB) on promoting plant growth in e-waste-amended soils and mobilizing trace metals into the plants. For this, a total of 18 bacteria were isolated and screened for e-waste tolerance. Screening for plant growth-promoting properties revealed the production of indole-3-acetic acid-like compounds, siderophore production, and phosphate solubilization. Identification based on 16S rRNA gene sequencing revealed that all isolates belonged to the genus Bacillus. Pot experiment revealed that the treated seeds showed the enhancement of chili plants root growth ranging from 106.55 to 208.07% compared to control plants (e-waste) and 0.0 to 47.90% (without e-waste). A similar enhancement was also observed in the shoot length, and size of the leaf compared to e-waste amended control plants. Inoculation of ETB significantly (p < 0.05) mobilized Fe, Zn, Cu, and Ni into chili plants. The identified ETB could be used to mitigate the toxicity posed by the e-waste, enhancing plant growth and mobilization of micronutrients into plants from e-waste.
Bacillus species identified in this study are the potential e-tolerant (PCB) PGP bacteria. Inoculation of e-tolerant bacteria resulted in increased plant growth attributes and biomass index in e-waste amended soil. Bacterial inoculation also showed maximum uptake of Cu, Fe, Zn, and Ni from the e-waste amended soil. This study demonstrated that micronutrients can be fortified/mobilized from e-waste using PGP bacteria.
Asunto(s)
Residuos Electrónicos , Contaminantes del Suelo , Oligoelementos , Suelo , ARN Ribosómico 16S/genética , ARN Ribosómico 16S/metabolismo , Biodegradación Ambiental , Bacterias/genética , Bacterias/metabolismo , Metales/metabolismo , Oligoelementos/metabolismo , Contaminantes del Suelo/metabolismo , Microbiología del SueloRESUMEN
Recurrent metastatic (RM) and locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN) are devasting disease states with limited therapeutic options and poor overall survival. Targeting the epidermal growth factor receptor (EGFR) is one area that has helped improve outcomes in this disease. Anti-EGFR based therapies have been shown to improve overall survival and mitigate the significant toxicities incurred from standard radiation, chemotherapy, and/or surgical options. Cetuximab, the most well-studied anti-EGFR monoclonal antibody, has demonstrated a positive impact on outcomes for RM and LA SCCHN. However, the development of early resistance to cetuximab highlights the need for a wider arsenal of therapy for RM and LA diseases. The use of immune checkpoint inhibitors has recently transformed the treatment of recurrent SCCHN. Drugs such as pembrolizumab and nivolumab have demonstrated success in recent clinical trials and have been approved for the treatment of advanced disease. Given the positive results of both EGFR targeted agents and immune checkpoint inhibitors, ongoing trials are studying their synergistic effects.
RESUMEN
Evans Syndrome (ES) is a rare autoimmune disorder that presents with simultaneous or sequential development of autoimmune hemolytic anemia (AIHA), thrombocytopenia, and/or neutropenia. This disease may occur in conjunction with other autoimmune disorders. Primary antiphospholipid syndrome (APS) is a disorder characterized by thrombosis, which can cause life-threatening complications such as fetal demise, strokes, or deep vein thrombosis. A 67-year-old male with type 2 diabetes mellitus, hypertension, and renal insufficiency presented with concomitant ES and APS. His hematological abnormalities began in 2013 after a deep vein thrombosis of the left lower extremity led to a diagnosis of APS and was started on chronic warfarin. In 2014, he was found to have immune thrombocytopenia (ITP) with relapses the following year. Several months later, he was hospitalized and diagnosed with AIHA. In the setting of his previous episodes of ITP and current AIHA, the diagnosis of ES was made. The initial treatment was 100 mg prednisone taper, but rituximab was required to make complete platelet recovery. The severe deterioration and rapid recovery with proper treatment of the patient highlights the importance of a timely diagnosis of ES. Mild thrombocytopenia can be associated with APS; however; severe thrombocytopenia may warrant further investigation for other possible causes. Maintaining ES on the differential diagnosis of patients with APS and thrombocytopenia could enhance health outcomes.